Abstract:Abstract Background The p38 alpha mitogen‐activated protein kinase (p38α) pathway is linked to both innate and adaptive immune responses, and is currently under investigation as a target for drug development in the context of Alzheimer’s disease (AD) and other conditions with neuroinflammatory dysfunction (Asih et al., 2020). Preclinical data indicates that p38α inhibition can protect against AD‐associated neuropathology, although the cellular mechanisms and signaling pathways that underlie these effects have not been fully elucidated. Evidence suggests that inhibition of p38α may provide benefit by modulating microglial‐associated neuroinflammatory processes that contribute to the development of AD pathology. The present study tests this hypothesis by assessing early‐stage pathological changes in AD model mice following microglial‐specific knock out (KO) of p38α. Methods KO of p38α in microglia was accomplished in 5‐month‐old C57BL/6J wild‐type and amyloidogenic AD model (APPswe/PS1dE9) mice using a tamoxifen‐inducible Cre/loxP system under control of the Cx3Cr1 promoter. Animals underwent behavioral assessment on the open field test at 7.5 months of age and on the radial arm water maze test at 11 months of age, followed by collection of cortical and hippocampal tissues. Other endpoint measures included quantification of proinflammatory cytokines, assessment of amyloid burden and plaque deposition, and characterization of microglia‐plaque dynamics using a combination of ELISA, immunohistochemical, and immunofluorescent techniques. Results Suppression of microglial p38α did not alter behavioral outcomes, proinflammatory cytokine levels, or overall amyloid plaque burden, but did significantly increase hippocampal levels of soluble Aβ42 and reduced hippocampal colocalization of Iba1 and 6E10 in a subset of microglia in close proximity to plaques. Conclusion This work suggests that rather than reducing inflammation per se, microglial p38α inhibition in the context of early AD‐type amyloid pathology may alter hippocampal microglia‐plaque interactions. Additionally, these results support future investigations of microglial p38α signaling at different stages of disease, as well as the potential relationship between p38α and phagocytic processes in this particular cell‐type. Funding : This work is supported by the National Institutes of Health (RF1 AG064859; F32 AG058456; T32 AG057461).

Serum Amyloid A Inhibits Astrocyte Migration Via Activating P38 MAPK

Astrocyte-Microglia Cross Talk through Complement Activation Modulates Amyloid Pathology in Mouse Models of Alzheimer's Disease.

Serum Amyloid a Differentially Activates Microglia and Astrocytes Via the PI3K Pathway.

Early Activation of Astrocytes Does Not Affect Amyloid Plaque Load in an Animal Model of Alzheimer’s Disease

Serum Amyloid a Attenuates Tau Phosphorylation in a Systemic Inflammation Model

Suppression of LPS-induced tau hyperphosphorylation by serum amyloid A

Astrocytic AT1R deficiency ameliorates Aβ-induced cognitive deficits and synaptotoxicity through β-arrestin2 signaling

Upregulation of Astrocytes Protein Phosphatase‐2a Stimulates Astrocytes Migration Via Inhibiting P38 MAPK in Tg2576 Mice

The Difference in Gliosis Induced by Β-Amyloid and Tau Treatments in Astrocyte Cultures Derived from Senescence Accelerated and Normal Mouse Strains

Inflammation-Dependent Cerebral Deposition of Serum Amyloid A Protein in A Mouse Model of Amyloidosis

Selective reduction of astrocyte apoE3 and apoE4 strongly reduces Aβ accumulation and plaque-related pathology in a mouse model of amyloidosis

Serum Amyloid A-Mediated Inflammasome Activation of Microglial Cells in Cerebral Ischemia.

Apolipoprotein Serum Amyloid A in Alzheimer's Disease.

Quantitative proteomics reveals that PEA15 regulates astroglial Aβ phagocytosis in an Alzheimer's disease mouse model

Effect of Regulation of Chemerin/Chemokine-like Receptor 1/Stimulator of Interferon Genes Pathway on Astrocyte Recruitment to Aβ Plaques

Secretome Analyses of Aβ1–42 Stimulated Hippocampal Astrocytes Reveal That CXCL10 is Involved in Astrocyte Migration

Stromal cell-derived factor 1α decreases β-amyloid deposition in Alzheimer's disease mouse model.

Murine Beta-Amyloid (1–42) Oligomers Disrupt Endothelial Barrier Integrity and VEGFR Signaling via Activating Astrocytes to Release Deleterious Soluble Factors

Amyloid-β1-42 Dynamically Regulates the Migration of Neural Stem/progenitor Cells Via MAPK-ERK Pathway.

Early loss of microglial p38α MAPK in the APPswe/PS1dE9 mouse model of Alzheimer’s disease alters soluble amyloid beta and reduces microglia co‐localization with amyloid plaques without affecting amyloid‐associated pathology

The Characteristics of Astrocyte on Aβ Clearance Altered in Alzheimer's Disease Were Reversed by Anti-Inflammatory Agent (+)-2-(1-hydroxyl-4-oxocyclohexyl) Ethyl Caffeate.